Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026000695?dgcid=rss_sd_all
Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026000695?dgcid=rss_sd_all
“Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.” Blood Neoplasia.
@article{article97590,
title = {Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026000695?dgcid=rss_sd_all}
}